and causes depression. Therefore, regular bowel movements are essential for maintaining a high quality of life. To improve bowel routine, the fiber intake should be increased to elevate the number of lactobacilli or bifidobacteria in the intestinal flora and lower the emission of putrefaction gases. Moreover, increasing fiber intake also improves constipation. However, there have only been a few studies investigating the beneficial effects of fiber intake on bowel movement in humans. Although evidence demonstrates how prebiotic fibers positively affect constipation and are usually recommended, the quality of evidence is still considered low.
Yeasts have been used for fermenting foods, such as bread, sake, and wine, since ancient times. Furthermore, yeast has been used for industrial and pharmaceutical purposes in the genetic and medical fields because it is unicellular with a simple biological structure.
Saccharomyces cerevisiae is a well-known yeast species. Considering its physiological activity, it is well known for its nutrient tonicity and mineral supplement effects associated with its rich nutrient contents. Moreover, yeast is known to improve bowel movement because it is rich in dietary fiber.
Therefore, we conducted a randomized, double-blind study to assess and compare the effects of a food with Saccharomyces cerevisiae NK-1 versus a placebo food.
METHODS

Study design
This was a randomized, placebo controlled, double-blind, parallel-group study. We included 50 individuals and equally divided them into two groups: The S. cerevisiae NK-1 group and placebo group. This clinical trial was carried out at Chiyoda Para-Medical Care Clinic. (Tokyo, Japan) The participants were all healthy adults Japanese with infrequent bowel movements (3-5 movements a week) and met the inclusion criteria listed in Table 1 . Informed consent was obtained from all the participants in written. The ethics committee of the Japan Conference of Clinical Research reviewed and approved the study prior to its implementation. Furthermore, the study plan was registered under the UMIN Clinical Trials Registry (UMIN #000020476). and was administered to the participants three times a day. The placebo food did not contain the S. cerevisiae NK-1 powder. Both food did not differ in terms of characteristics, including color, smell, and size. The ingredients of the test and placebo food are listed in Table 2 .
Bowel movement
Throughout the study period, participants frequently answered questionnaires investigating fecal characteristics, including the number of bowel movements and volume of stool (number of medium egg-sized stools) per day.
Adverse events
Hematological and blood biochemical tests were conducted before and after 4, 8, and 12 weeks of consuming the food. Participants were also interviewed regarding any adverse events faced during each hospital visit to investigate causal relationships and severity. The Mann-Whitney U-test and Wilcoxon signed-rank test were performed to assess the number of days with bowel movement and number of bowel movements. The level of statistical significance was set at 5%. Adverse events were examined using Fisher's exact test. Statistical analyses were conducted at the Kansai University of Welfare Sciences using the SAS software version 9.4 (SAS Inc.)
Statistical analysis
RESULTS
Analysis set
In total, 50 participants were included (25 per group). Three participants from each group dropped out half-way through the study due to personal reasons. Therefore, the final analysis set for efficacy and safety included only 44 participants. In the test period, Participants did not change water intake and meal amount. The weight of participants did not change. Table 3 presents the profiles of all the included participants.
Bowel movement and stool volume
Stool frequency was calculated daily and tallied weekly. The study results are presented in Table 4 (average calculated every four weeks) and Figure 1 (average calculated every week).
After 4, 8, and 12 weeks of consuming the test food (p < 0.05), the number of days with bowel movement/week increased significantly in the test group compared to the placebo group. The stool volume significantly increased in the test group compared to the placebo group after 8
and 12 weeks of consuming the test food (p < 0.05). Figure 2 shows the increase in stool frequency per day, which significantly increased in the test group compared to the placebo group after 4 and 8 weeks of consuming the test food (p < 0.05). Table 4 significantly increased in the test group compared to the placebo group (p < 0.05).
Volume of stool (day/week) was calculated by number of medium egg-sized stools. #;
significantly increased in the test group compared to the placebo group (p < 0.05).
DISCUSSION
The results of the present study indicated that 4, 8, and 12 weeks of consuming the test food resulted in a significantly higher frequency of bowel movement in the test group than in the control group.
Probiotics are living bacteria, viruses, parasites, or yeasts that are beneficial to the consumer. The administration of probiotics is considered promising, safe, and acceptable for treating constipation and irritable bowel syndrome (IBS). Most studies evaluating the effects of probiotics on patients with IBS have been performed using bacterial strains of lactobacilli and/or bifidobacteria [7] . Compared with bacteria, yeasts have numerous benefits, which include antibiotic and phage resistance, higher natural robustness against gastric acid and bile salts, and stronger capacity to regulate innate immune response [8] . However, only two clinical trials to date have assessed the effects of yeast in patients with IBS [9, 10] . No study has yet assessed the effect of yeasts in individuals with constipation. give rise to dendrites. These features indicate that yeasts can easily proliferate in the intestine.
Furthermore, because this microorganism promotes the production of good bacteria in the
